Document is current
Any future updates will be listed below
-
Authors
Saldajeno, Don Pietro
Kawaoka, Shinpei
Masuda, Norikazu https://orcid.org/0000-0002-7302-0278
Tanaka, Sunao
Bando, Hiroko
Nishimura, Tomomi https://orcid.org/0009-0008-1999-5147
Kadoya, Takayuki
Yamanaka, Takashi
Imoto, Shigeru
Velaga, Ravindranath M.
Tamura, Nobuko
Aruga, Tomoyuki
Ikeda, Kazushi
Fukui, Yukiko
Maeshima, Yurina
Takada, Masahiro
Suzuki, Eiji
Ueno, Takayuki https://orcid.org/0000-0002-9080-9377
Ogawa, Seishi
Haga, Hironori
Ohno, Shinji https://orcid.org/0000-0003-2093-3353
Morita, Satoshi
Kawaguchi, Kosuke https://orcid.org/0000-0002-3161-7981
Toi, Masakazu https://orcid.org/0000-0003-1488-9958
- License Information
-
More Information
Article History
Received: 27 February 2023
Revised: 12 October 2023
Accepted: 27 November 2023
First Online: 18 January 2024
Competing interests
: NM: grants from Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa-Kirin, and Nippon-Kayaku; honoraria from Chugai, Pfizer, AstraZeneca, Eli Lilly, and Eisai; executive board and board of directors of JBCRG. TY: honoraria from AstraZeneca, Daiichi-Sankyo, Eli Lilly, Novartis, Chugai, Eisai, Kyowa-Kirin, and Pfizer. SI: honoraria from Eisai, Taiho, Chugai, Kyowa-Kirin, Daiichi-Sankyo, and Nippon-Kayaku. NT: grant from Eisai; honoraria from Chugai, Pfizer, Eli Lilly, Novartis, Eisai, and AstraZeneca KK. TA: honoraria from Chugai, Pfizer, Eli Lilly, and AstraZeneca KK. MT: grants from Daiichi-Sankyo, AstraZeneca KK, Yakult, KBCRN, ABCSG, JBCRG and Medbis; honoraria from Chugai, Eisai, Daiichi-Sankyo, Eli Lilly, AstraZeneca, Pfizer, Nippon-Kayaku, and Mitaka Koki. TU: honoraria from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca, Novartis Pharma. SO: grants from Takeda Foundation, ChordiaTherapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd.; Royalties from ASAHI Genomics Inc, Qiagen and Cordia Therapeutics; Consulting fees from KAN Research Institute, Inc., ChordiaTherapeutics, Inc., Eisai Co., Ltd., Novartis Pharmaceuticals; honoraria from MSD Japan, Kyowa Hakko Kirin Co., Ltd., Pfizer Inc; Stock or stock options from Stock of ASAHI Genomics Inc, Stock potion of Cordia Therapeutics Inc., and Stock of Rebirthell Inc. SO: honoraria from Eli Lilly, Chugai, Pfizer, and Eisai. SM: grants from Nippon Boehringer Ingelheim, Eisai; honoraria from AstraZeneca, Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical, Nippon Boehringer Ingelheim, Bristol Myers Squibb Co. Ltd., Novartis Pharma KK, MSD KK, Kyowa-Kirin Co. Ltd., Astellas Pharma, Pfizer Japan, Ono Pharmaceutical Co. Ltd., Eli Lilly Japan. KK: grants from TERUMO, Astellas, Eli Lilly, Kyoto Breast Cancer Research Network; consulting fees from Becton Dickinson Japan; honoraria from Eisai, Chugai, and Takeda. MT: grants from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG Associates, Eisai, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon-Kayaku, AFI Technology, Luxonus, Shionogi, and GL Science; honoraria from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, and Nippon-Kayaku; advisory board of Kyowa-Kirin, Daiichi-Sankyo, Eli Lilly, Konica Minolta, BMS, Athenex Oncology, Bertis, Terumo, Kansai Medical Net; board of directors of JBCRG Associates, KBCRN, OOTR; associate editor of the British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women’s Cancer, Asian Journal of Surgery, Asian Journal of Breast Surgery; deputy editor of International Journal of Oncology.
: Not applicable.
: Not applicable.
